Key Developments: Nestle SA (NESN.VX)

NESN.VX on Virt-X Level 1

74.85CHF
6:03am EST
Change (% chg)

CHF0.25 (+0.34%)
Prev Close
CHF74.60
Open
CHF74.45
Day's High
CHF75.15
Day's Low
CHF74.40
Volume
1,664,611
Avg. Vol
8,954,854
52-wk High
CHF75.45
52-wk Low
CHF63.85

Search Stocks

Latest Key Developments (Source: Significant Developments)

Nestle SA to propose increase in dividend
Thursday, 19 Feb 2015 02:03am EST 

Nestle SA:To propose an increase in the dividend to CHF 2.20 per share.Last trading day with entitlement to receive the dividend is April 17.Net dividend will be payable as from April 22.Shareholders who are on record in the share register with voting rights on April 9 will be entitled to exercise their voting rights.  Full Article

L'Oreal and Nestle end joint venture Inneov
Thursday, 27 Nov 2014 12:01pm EST 

L'Oreal SA and Nestle:Announce project to end their joint venture Inneov during course of Q1 2015.Say brand has not met development expected by both partners.Say both partners will keep benefits of research and intellectual property as well as developments achieved which could be potentially used in their respective field.Say to be committed to review all employment opportunities within their Groups for all employees of Inneov.  Full Article

Nestle SA confirms FY 2014 sales outlook
Thursday, 16 Oct 2014 01:15am EDT 

Nestle SA:Says is still aiming for organic sales growth of around 5 pct for FY 2014.  Full Article

Nestle SA confirms FY 2014 outlook; plans to launch 8 billion Swiss francs share buy-back programme
Thursday, 7 Aug 2014 01:15am EDT 

Nestle SA:Says FY 2014 outlook confirmed: organic growth around 5 pct and improvements in margins, underlying earnings per share in constant currencies and capital efficiency.Plans to launch new share buy-back programme of 8 billion Swiss francs that will start this year and continue into 2015.  Full Article

Nestle SA completed acquisition of Valeant Pharmaceuticals's commercialisation rights
Thursday, 10 Jul 2014 09:35am EDT 

Nestle SA:Completed its acquisition of Valeant Pharmaceuticals International's commercialisation rights to several key injectable aesthetic dermatology products in US and Canada, as announced on May 28.These rights will be integrated into NestlĂ© Skin Health and commercialised by Galderma.  Full Article

L'Oreal finalizes disposal of its 50 pct ownership in Galderma to Nestle
Tuesday, 8 Jul 2014 12:00pm EDT 

L'Oreal SA:Finalizes disposal of its 50 pct ownership in Galderma to Nestle.  Full Article

Valeant Pharmaceuticals International Inc to sell Filler And Toxin assets to Nestle
Wednesday, 28 May 2014 01:15am EDT 

Valeant Pharmaceuticals International Inc:Agreement to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 bln in cash.Nestle expects to complete acquisition of Galderma S.A. in July and would expect to operate acquired assets through Galderma.Transaction is subject to customary closing conditions, including clearance or early expiration of waiting period under Hart-Scott-Rodino (HSR) Act and is not contingent upon successful transaction with Allergan, Inc.Transaction is extremely attractive both to Valeant and Galderma, and dovetails well with our announced plans for a transaction with Allergan.  Full Article

Nestle SA confirms FY 2014 outlook
Tuesday, 15 Apr 2014 02:00am EDT 

Nestle SA:Confirms fiscal 2014 outlook.Says performance will be weighted to second half, outperforming market, with organic growth around 5 pct. and improvements in margins, underlying earnings per share (EPS) in constant currencies and capital efficiency.  Full Article

Nestle SA Chairman to step down from his position in 2017
Saturday, 5 Apr 2014 12:07am EDT 

Nestle SA:Says Chairman Peter Brabeck-Letmathe to step down form his position in 2017.  Full Article

L'Oreal and Nestle sign mixed share purchase agreement
Monday, 24 Mar 2014 03:30am EDT 

L'Oreal SA:Says to have signed on March 21 mixed share purchase agreement with Nestle SA to acquire 48,500,000 own shares, representing 8 pct of share capital.Acquisition conditioned upon sale to Nestle of company's holding in Galderma.Sale completion conditional upon approval of competition authorities.  Full Article

Nestle Nigeria slows capex as consumers feel devaluation pinch

LAGOS - Nestle Nigeria's chief executive expects the firm's capital expenditure to slow to its lowest level in five years after a currency devaluation dampened customer spending in Africa's biggest economy.

Search Stocks